VBL Therapeutics (VBLT) Tops Q3 EPS by 3c

VBL Therapeutics (NASDAQ: VBLT) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15).

At September 30, 2016, the Company had cash, cash equivalents and short-term bank deposits totaling $48.9 million and working capital of $46.0 million. We expect that our cash, cash equivalents and short-term bank deposits will enable us to fund our operating expenses and capital expenditure requirements into 2019. Our cash position is expected to be sufficient for completion of our on-going Phase 3 clinical trial of VB-111 in rGBM, for a potential registration trial of VB-111 in ovarian cancer and to support the investment in the new Modiin facility.

For earnings history and earnings-related data on VBL Therapeutics (VBLT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15